FGFR3, PTPN11, NF1); NFKB (TRAF3, TRAF2, CYLD, BIRC2/3, MAPK3K14); TP53/MDM2; RB1/CDKN2C; and others (DIS3, FAM46C). One of these pathways is dysregulated in more than 95% of people with multiple ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

In addition, 38 human myeloma cell lines, tonsil plasma cells, bone marrow PCs, normal plasmablasts, tonsil B cells, and peripheral blood B cells were also analyzed. Further genomic analysis of ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...

Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg ...

The drug targets changes in the FGFR3 gene that drive tumor growth in about 10%-20% of these patients. Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in ...

The drug targets changes in the FGFR3 gene that drive tumour growth in about 10%-20% of these patients. Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in ...

Specifically, the indication covers eligible patients harboring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received at least one line of ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.